Khalid Iqbal is Professor of Neuroscience and Chairman of the Department of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York. He received his PhD degree in Biochemistry from the University of Edinburgh, UK.
Dr. Iqbal received the prestigious Potamkin Prize for Alzheimer Disease Research from the American Academy of Neurology, the Zenith Award from the Alzheimer’s Association, USA, and an Honorary Doctor of Science degree from the City University of New York College of Staten Island for his ground-breaking work on neuronal protein pathology and discoveries of tau protein and its abnormal hyperphosphorylation in Alzheimer’s disease (AD).
In 2007, the Alzheimer’s Association, USA, established the Khalid Iqbal Lifetime Achievement Award for Alzheimer’s Disease Research, which is given out annually at the International Conference on Alzheimer’s Disease to a senior distinguished AD researcher.
Dr. Iqbal’s discovery of the neurotrophic compound P021 and the strategy of shifting balance from neurodegeneration to regeneration of the central nervous system as a novel therapeutic approach has won him several patents for the treatment of AD and related neurodegenerative conditions.
He has authored over 400 scientific papers in prestigious American and international scientific journals and edited seven books on research advances in AD and related neurodegenerative disorders. As of November 21, 2020, his scientific publications have received 51,574 citations and an h-index of 116. He currently serves on the editorial boards of several journals and scientific advisory committees of biotechnology companies.
Dr. Iqbal is also the Founding President of the Promotion of Education in Pakistan (PEP) Foundation, Inc., New York, and has been supporting the higher education sector in Pakistan since 1994. His services to science and technology in Pakistan won him election as a Foreign Fellow of the Pakistan Academy of Sciences in December 2019.
